G. Tollefson

发表

Time-lapse mapping of cortical changes in schizophrenia with different treatments.

J. Lieberman, G. Bartzokis, A. Toga, 2009, Cerebral cortex.

Antipsychotic drug effects on brain morphology in first-episode psychosis.

J. Lieberman, R. Kahn, R. Gur, 2005, Archives of general psychiatry.

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

W W Offen, A. Levey, S. Gauthier, 1997, Archives of neurology.

Occurrence of myoclonus in patients treated with cyclic antidepressants.

G. Tollefson, M. Garvey, 1987, Archives of general psychiatry.

Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety.

G. Tollefson, P. Londborg, W. Smith, 1999, Journal of clinical psychopharmacology.

How long to onset of antidepressant action: a meta‐analysis of patients treated with fluoxetine or placebo

G. Tollefson, S. Holman, 1994, International clinical psychopharmacology.

Pharmacotherapy of obsessive compulsive disorder‐experience with fluoxetine

G. Tollefson, M. Birkett, A. Wood, 1993, International clinical psychopharmacology.

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

G. Tollefson, C. Beasley, W. Satterlee, 1996, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic

G. Tollefson, H. Ascher-Svanum, B. Kinon, 2005, Journal of psychopharmacology.

A comparison of first and second generation antidepressants at the human muscarinic cholinergic receptor.

G. Tollefson, S. Senogles, 1983, Journal of clinical psychopharmacology.

Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy.

I. Bitter, S. Hirsch, W. Gaebel, 1997, International journal of psychiatry in clinical practice.

Acute Effects of Fluoxetine Versus Placebo on Functional Health and Well-Being in Late-Life Depression

J. Ware, G. Tollefson, K. Beusterien, 1995, International Psychogeriatrics.

A Double-Blind, Placebo-Controlled Clinical Trial of Fluoxetine in Geriatric Patients With Major Depression

G. Tollefson, J. Potvin, J. Heiligenstein, 1995, International Psychogeriatrics.

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

D. Revicki, G. Tollefson, E. Edgell, 1999, PharmacoEconomics.

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

G. Tollefson, C. Beasley, W. Satterlee, 1996, Psychopharmacology.

The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features

R. Shelton, S. Stahl, M. Tohen, 2000, Schizophrenia Research.

A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo

G. Tollefson, B. Kinon, M. Dellva, 1998, European Neuropsychopharmacology.

Review of recent clinical studies with olanzapine

G. Tollefson, A. Kuntz, 1999, British Journal of Psychiatry.

Controlled, Double-blind Investigation of the Clozapine Discontinuation Symptoms With Conversion to Either Olanzapine or Placebo

J. Kane, G. Tollefson, B. Kinon, 1999 .

Olanzapine plus fluoxetine: Double-blind and open-label results in treatment-resistant major depressive disorder

R. Shelton, S. Stahl, M. Tohen, 1999, European Neuropsychopharmacology.

Long-term olanzapine treatment: Efficacy and safety in manic patients with and without psychotic features

M. Tohen, G. Tollefson, T. Sanger, 1999, European Neuropsychopharmacology.

Olanzapine reduces psychotic symptoms and behavioral disturbances associated with alzheimer's disease

G. Tollefson, W. S. Clark, T. Sanger, 2000, Schizophrenia Research.

P.2.015 Olanzapine versus haloperidol: Analysis of schizophrenic patients from the multi-center international trial

G. Tollefson, C. Beasley, A. Crawford, 1997, European Neuropsychopharmacology.

Olanzapine: Acute and long-term efficacy in bipolar I patients

M. Tohen, G. Tollefson, T. Sanger, 2000, Schizophrenia Research.

Safety of olanzapine.

G. Tollefson, C. Beasley, P. Tran, 1997, The Journal of clinical psychiatry.

Effect of long-term olanzapine treatment on weight change in schizophrenia

G. Tollefson, B. Kinon, B. Basson, 2000, Schizophrenia Research.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

G. Tollefson, B. Kinon, B. Basson, 2001, The Journal of clinical psychiatry.

Comparison of major depressions with and without panic attacks.

G. Tollefson, V. Tuason, M. Garvey, 1987, Comprehensive psychiatry.

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

G. Tollefson, B. Kinon, B. Basson, 2001, The Journal of clinical psychiatry.

Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.

M. Detke, S. Brannan, G. Tollefson, 2005, Journal of psychiatric research.

Depressives syndromes in a primary care setting: evaluation, classification, and outcome.

G. Tollefson, V. Tuason, E. Hughes, 1983, Comprehensive psychiatry.

Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?

G. Tollefson, S. Andersen, 1999, The Journal of clinical psychiatry.

Is There a Relationship between Baseline and Treatment-Associated Changes in [3H]-IMI Platelet Binding and Clinical Response in Major Depression?

C. Nemeroff, G. Tollefson, D. Knight, 1996, Neuropsychopharmacology.

A comparison of peripheral and central human muscarinic cholinergic receptor affinities for psychotropic drugs.

G. Tollefson, V. Tuason, W. Frey, 1982, Biological psychiatry.

Alprazolam in the treatment of obsessive symptoms.

G. Tollefson, 1985, Journal of clinical psychopharmacology.

The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials

G. Tollefson, W. Potter, D. Faries, 2001, Journal of clinical psychopharmacology.

Olanzapine versus placebo in the treatment of acute mania

M. Tohen, S. McElroy, G. Tollefson, 1998, European Psychiatry.

Lymphopenia in primary degenerative dementia.

G. Tollefson, M. Garvey, M. Luxenberg, 1989, Journal of psychiatric research.

Migraine headaches and depression.

G. Tollefson, M. Garvey, C. Schaffer, 1984, The American journal of psychiatry.

Comorbid Irritable Bowel Syndrome in Patients with Generalized Anxiety and Major Depression

G. Tollefson, M. Luxenberg, S. L. Tollefson, 1991 .

The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease

F. Bymaster, P. Trzepacz, G. Tollefson, 2001, International journal of geriatric psychiatry.

Hypersomnia in major depressive disorders.

D. Mungas, G. Tollefson, M. Garvey, 1984, Journal of affective disorders.

The influence of pharmacotherapy on selfdirected and externally-directed aggression in schizophrenia

G. Tollefson, J. Potvin, C. Beasley, 1998, Schizophrenia Research.

Does cold winter weather produce depressive symptoms?

G. Tollefson, M. Garvey, C. Furlong, 1988, International journal of biometeorology.

Comments on "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders" by Tran and Associates: Reply to Kasper and Kufferle

G. Tollefson, P. Tran, 1998 .

Distinguishing myasthenia gravis from conversion.

G. Tollefson, 1981, Psychosomatics.

Course of psychomotor agitation during pharmacotherapy of depression: Analysis from double‐blind controlled trials with fluoxetine

G. Tollefson, M. Sayler, 1996, Depression and anxiety.

Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder

J. Erickson, E. Dunayevich, G. Tollefson, 2008, Neuropsychopharmacology.

Serotonin and alcohol: interrelationships.

G. Tollefson, 1989, Psychopathology.

Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia

J. Lieberman, R. Gur, M. Tohen, 2003, Schizophrenia Research.

Association of affective disorder with migraine headaches and neurodermatitis.

G. Tollefson, M. Garvey, 1988, General hospital psychiatry.

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

J. Lieberman, R. Kahn, R. Gur, 2005, British Journal of Psychiatry.

Costs of olanzapine treatment compared with haloperidol for schizophrenia: Results from a randomized clinical trial

D. Revicki, G. Tollefson, S. Hamilton, 1998, Schizophrenia Research.

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

G. Tollefson, C. Beasley, A. Crawford, 1997, Schizophrenia Research.

StandardOlanzapineVersusPlacebo and Ineffective-Dose Olanzapinein the MaintenanceTreatmentof Schizophrenia

G. Tollefson, C. Beasley, Mary Anne Ddilva, 1997 .

Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.

J. Kane, G. Tollefson, B. Kinon, 1999, Journal of clinical psychopharmacology.

Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia

G. Tollefson, M. Jakovljevič, L. Hotujac, 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Is the distinction between situational and nonsituational primary depression valid?

D. Mungas, G. Tollefson, M. Garvey, 1984, Comprehensive psychiatry.

Comments on Article by Tran and Associates, "Double-Blind Comparison of Olanzapine Versus Risperidone in Treatment of Schizophrenia and Other Psychotic Disorders": Reply

G. Tollefson, P. Tran, 1998 .

Included Studies (n = 120)

T. Su, C. M., I. G, 2022 .

Treatment of Comorbid Deneralized Anxiety in a Recently Detoxified Alcoholic Population with a Selective Serotonergie Drug (Buspirone)

G. Tollefson, S. L. Tollefson, J. Montague-Clouse, 1992 .

Efficacy of olanzapine: an overview of pivotal clinical trials.

G. Tollefson, C. Beasley, P. Tran, 1997, The Journal of clinical psychiatry.

Olanzapine in the treatment of schizoaffective disorder

G. Tollefson, C. Beasley, P. Tran, 1998, Schizophrenia Research.

543 Olanzapine in the treatment of chizoaffective disorder

G. Tollefson, Yili Lu, C. Beasley, 1997, Schizophrenia Research.

539 Treatment failure with clozapine: Can olanzapine be the alternative therapy?

G. Tollefson, M. Birkett, D. Shoshani, 1997, Schizophrenia Research.

OLANZAPINE ON TRIAL. AUTHORS' REPLY

C. Barbui, G. Tollefson, B. Capehart, 1998 .

Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol

G. Tollefson, Yili Lu, T. Sanger, 1998, European Neuropsychopharmacology.

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.

A. Rush, M. Jenike, W. Goodman, 1994, Archives of general psychiatry.

A Case of Neuroleptic Malignant Syndrome: In Vitro Muscle Comparison with Malignant Hyperthermia

G. Tollefson, 1982, Journal of clinical psychopharmacology.

Depressive episodes following alcohol intoxication.

G. Tollefson, M. Garvey, 1982, Psychosomatics.

Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam.

G. Tollefson, T. Lew, 1983, Biological psychiatry.

A meta-analysis of the use of typical antipsychotic agents in bipolar disorder.

M. Tohen, G. Tollefson, C. Zarate, 2001, Journal of affective disorders.

Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.

G. Tollefson, J. Potvin, M. Sayler, 1994, The Journal of clinical psychiatry.

The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency.

G. Tollefson, S. Lancaster, J. Montague-Clouse, 1991, Psychopharmacology bulletin.

Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis

Jeffrey A. Lieberman, Larry J. Seidman, Robert M. Hamer, 2006, Biological Psychiatry.

An open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder.

G. Tollefson, R. Valentine, M. Luxenberg, 1991, The Journal of clinical psychiatry.

A Double-Blind, Controlled Comparison of the Novel Antipsychotic Olanzapine versus Haloperidol or Placebo on Anxious and Depressive Symptoms Accompanying Schizophrenia

G. Tollefson, C. Beasley, P. Tran, 1998, Biological Psychiatry.

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

R. Tamura, G. Tollefson, C. Beasley, 1997, The American journal of psychiatry.

Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder

J. Erickson, E. Dunayevich, G. Tollefson, 2008, Neuropsychopharmacology.

The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population.

G. Tollefson, S. Lancaster, J. Montague-Clouse, 1991, The Journal of neuropsychiatry and clinical neurosciences.

Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.

J. Fawcett, G. Tollefson, G. Winokur, 1993, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

R. Shelton, M. Case, G. Tollefson, 2005, The Journal of clinical psychiatry.

A novel augmentation strategy for treating resistant major depression.

Wei Zhang, R. Shelton, S. Stahl, 2001, The American journal of psychiatry.

Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia

G. Tollefson, 1990, Biological Psychiatry.

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.

R. Tamura, J. Cummings, K. Gannon, 2000, Archives of general psychiatry.

Ecological Studies of Antidepressant Treatment and Suicidal Risks

M. Tohen, R. Baldessarini, L. Tondo, 2007, Harvard review of psychiatry.

A randomized, double‐blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment‐resistant depression

M. Case, G. Tollefson, S. Briggs, 2006, Depression and anxiety.

Zonisamide-induced mania.

G. Tollefson, C. L. Charles, L. Stoesz, 1990, Psychosomatics.

A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features

M. Tohen, G. Tollefson, A. Rothschild, 2004, Journal of clinical psychopharmacology.

SAT-5-5 Olanzapine: An exciting atypical antipsychotic — the clinical experience

G. Tollefson, C. Beasley, P. Tran, 1995, European Neuropsychopharmacology.

Hyperadrenergic hypomania consequent to the abrupt cessation of clonidine.

G. Tollefson, 1981, Journal of Clinical Psychopharmacology.

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.

J. Erickson, E. Dunayevich, G. Tollefson, 2010, Addictive behaviors.

Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders

Stephen B. Thomas, A. Rush, M. Blehar, 2002, Biological Psychiatry.

A cholinergic role in the mechanism of lithium in mania.

G. Tollefson, S. Senogles, 1983, Biological psychiatry.

Assessing and interpreting treatment effects in longitudinal clinical trials with missing data

Geert Molenberghs, Craig H Mallinckrodt, Raymond J Carroll, 2003, Biological Psychiatry.

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.

G. Tollefson, G D Tollefson, T M Sanger, 1997, The American journal of psychiatry.

Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis

J. Lieberman, M. Tohen, G. Tollefson, 1999 .

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.

J. Calabrese, M. Tohen, P. Mitchell, 2003, Archives of general psychiatry.

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

M. Tohen, S. McElroy, P. Janicak, 2000, Archives of general psychiatry.

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.

R. Tamura, G. Tollefson, J. Potvin, 1997 .

Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent

G. Tollefson, C. C. Taylor, 2006 .

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.

G. Tollefson, J. Potvin, C. Beasley, 1997, The Journal of clinical psychiatry.

Psychiatric implications of anticonvulsant drugs.

G. Tollefson, 1980, The Journal of clinical psychiatry.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

J. Lieberman, R. Kahn, R. Gur, 2003, The American journal of psychiatry.

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

G. Tollefson, J. Potvin, P. Tran, 1997 .

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

G. Tollefson, M. Birkett, A. Wood, 2001, Biological Psychiatry.

The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.

R. Belmaker, G. Tollefson, H. Munitz, 2000, Clinical therapeutics.

Olanzapine versus haloperidol in the treatment of schizoaffective disorder

G. Tollefson, Yili Lu, C. Beasley, 1999, British Journal of Psychiatry.

Olanzapine versus Placebo and Haloperidol

Charles M Beasley, G. Tollefson, C. Beasley, 1996, Neuropsychopharmacology.

Acute Dysphoric Mania: Treatment Response to Olanzapine Versus Placebo

M. Tohen, J. Fawcett, R. Baker, 2003, Journal of clinical psychopharmacology.

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.

D. Kupfer, J. Calabrese, M. Tohen, 2002, Archives of general psychiatry.

Evaluation of Suicidalitv During Pharmacolonic Treatmeit of Mgod and NonmoGd Disorders

J. Fawcett, G. Tollefson, G. Winokur, 1993 .

The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone

G. Tollefson, P. Tran, S. Andersen, 1999, Biological Psychiatry.

Delirium induced by the competitive interaction between phenytoin and dipropylacetate.

G. Tollefson, 1981, Journal of clinical psychopharmacology.

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

R. Tamura, G. Tollefson, W. Glazer, 1999, British Journal of Psychiatry.

Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia

J. Lieberman, R. Gur, M. Tohen, 2003, Schizophrenia Research.

A Circulating Lupus‐like Coagulation Inhibitor Induced by Chlorpromazine

G. Tollefson, M. Cusulos, K. Rodysill, 1984, Journal of clinical psychopharmacology.

Imipramine metabolism in recurrent depressive episodes.

G. Tollefson, R. Valentine, V. Tuason, 1985, Journal of affective disorders.

Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success.

G. Tollefson, D. Goldstein, P. Roback, 1995, Obesity research.

Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.

G. Enas, G. Tollefson, J. Potvin, 1994, Journal of clinical psychopharmacology.

Absence of emergent suicidal ideation during treatment: A comparative, controlled, double‐blind analysis employing several distinct antidepressants

G. Tollefson, M. Luxenberg, M. Sayler, 1994 .

Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group.

R. Tamura, M. Pollack, M. Demitrack, 1998, The American journal of psychiatry.

Is Baseline Agitation a Relative Contraindication for a Selective Serotonin Reuptake Inhibitor: A Comparative Trial of Fluoxetine Versus Imipramine

J. Greist, J. Jefferson, G. Tollefson, 1994, Journal of clinical psychopharmacology.

Is chronic primary major depression a distinct depression subtype?

G. Tollefson, V. Tuason, M. Garvey, 1986, Comprehensive psychiatry.

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

G. Tollefson, C. Beasley, M. Dellva, 1998, British Journal of Psychiatry.

Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression

P. Bech, G. Tollefson, J. Boissel, 2000, British Journal of Psychiatry.

Rational Design of a Combination Medication for the Treatment of Obesity

K. Gadde, F. Greenway, K. Fujioka, 2009, Obesity.

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.

A Labelle, E. Stip, G. Tollefson, 2000, Archives of general psychiatry.

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.

F. Greenway, K. Fujioka, M. Guttadauria, 2009, The Journal of clinical endocrinology and metabolism.

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

K. Gadde, F. Bymaster, G. Tollefson, 2008, Neuropsychopharmacology.

Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial

Gerald Q. Maguire, D. Jeste, F. Bymaster, 2003, International journal of geriatric psychiatry.

Anxiety and Alcoholism: A Serotonin Link

G. Tollefson, 1991, British Journal of Psychiatry.

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

D. Wong, K. Perry, F. Bymaster, 2000, Neuropsychopharmacology.

Monoamine oxidase inhibitors: a review.

G. Tollefson, 1983, The Journal of clinical psychiatry.

A descriptive analysis of minor depression.

D. Kupfer, A. Rush, M. Thase, 2002, The American journal of psychiatry.

Prevalence of misuse of prescribed benzodiazepines in patients with primary anxiety disorder or major depression.

G. Tollefson, M. Garvey, 1986, The American journal of psychiatry.

Olanzapine versus haloperidol in the treatment of first episode psychosis

J. Lieberman, M. Tohen, G. Tollefson, 1998, Schizophrenia Research.

Ionic regulation of antagonist binding to the human muscarinic cholinergic receptor of caudate nucleus.

G. Tollefson, S. Senogles, William H Frey II, 1982, Journal of psychiatric research.

24 Hour Urinary Dehydroepiandosterone Sulfate in Unipolar Depression Treated with Cognitive and/or Pharmacotherapy

G. Tollefson, V. Tuason, M. Garvey, 1990 .

Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone).

G. Tollefson, S. L. Tollefson, J. Montague-Clouse, 1992, Journal of clinical psychopharmacology.

Differentiating anxiety and depression.

G. Tollefson, 1990, Psychiatric medicine.

The functional-organic dichotomy in new patient evaluations by residents in family practice.

G. Tollefson, E. Hughes, M. Garvey, 1984, Comprehensive psychiatry.

540 Olanzapine versus risperidone in the treatment of psychosis. Preliminary report

G. Tollefson, P. Tran, S. Hamilton, 1997, Schizophrenia Research.

Olanzapine vs placebo in the treatment of acute mania

M. Tohen, S. McElroy, G. Tollefson, 1998, Schizophrenia Research.

Olanzapine-fluoxetine combination for treatment of psychotic depression

G. Tollefson, S. Dubé, T. Sanger, 2002, European Psychiatry.

Olanzapine vs. placebo in rapid-cycling bipolar disorder

M. Tohen, G. Tollefson, T. Sanger, 1998, Schizophrenia Research.

Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.

G. Tollefson, D. Faries, J. Heiligenstein, 1994, Journal of affective disorders.

Adverse drug reactions/interactions in maintenance therapy.

G. Tollefson, 1993, The Journal of clinical psychiatry.

Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective, and schizophreniform disorders

J. Lieberman, R. Gur, M. Tohen, 2003, Schizophrenia Research.

Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.

M. Thase, M. Tohen, M. Case, 2007, Bipolar disorders.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404))

J. Lieberman, R. Kahn, R. Gur, 2009 .

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

G. Tollefson, C. Beasley, V. Sutton, 2003, Journal of clinical psychopharmacology.

Current issues in the psychopharmacology of schizophrenia

F. Bymaster, G. Tollefson, A. Breier, 2001 .

Predicting response to fluoxetine in geriatric patients with major depression.

D. Jeste, L. Koran, G. Tollefson, 1995, Journal of clinical psychopharmacology.

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

G. Tollefson, A. Breier, P. Feldman, 2003, The Journal of clinical psychiatry.

A double‐blind trial of fluoxetine, 20 mg, and placebo in out‐patients with DSM‐III-R major depression and melancholia

G. Tollefson, D. Faries, J. Heiligenstein, 1993, International clinical psychopharmacology.

Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.

D. Kupfer, A. Rush, M. Thase, 2004, The American journal of psychiatry.

Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: The absence of an effect related to agitation and suicidal behavior

J. Wernicke, G. Tollefson, S. Koke, 1997, Depression and anxiety.

Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes

G. Tollefson, J. Potvin, E. Souêtre, 1993, International clinical psychopharmacology.

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

J. Lieberman, R. Gur, D. Yurgelun-Todd, 2004, The American journal of psychiatry.

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.

G. Tollefson, C. Beasley, M. Dellva, 1997, Psychiatric services.

Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine

R. Tamura, M. Pollack, R. Lydiard, 1999, British Journal of Psychiatry.

Anxious–depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?

G. Tollefson, T. Sanger, 1999, Schizophrenia Research.

No gender differences in placebo responses of patients with major depressive disorder

G. Tollefson, R. Casper, M. Nilsson, 2001, Biological Psychiatry.

Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients

A. Rush, H. Roffwarg, D. Dunner, 1994, Psychiatry Research.

Drs. Tollefson and Sanger Reply

G. Tollefson, T. Sanger, 1998 .

Olanzapine versus risperidone and haloperidol in treatment of schizophrenia

G. Tollefson, B. Jones, 1998, Schizophrenia Research.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*

A. Nierenberg, J. Greist, G. Tollefson, 2007, Current medical research and opinion.

Cognitive function in schizophrenic patients.

G. Tollefson, Gary D. Tollefson, 1996, The Journal of clinical psychiatry.

Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain

G. Tollefson, S. Saxena, T. Ala, 1994, Brain Research.

Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.

L. Koran, G. Tollefson, M. Birkett, 1994, The Journal of clinical psychiatry.

Elevations of urinary MHPG in depressed patients with panic attacks

G. Tollefson, M. Garvey, P. Orsulak, 1987, Psychiatry Research.

Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.

R. Belmaker, G. Tollefson, M. Dossenbach, 2001, The Journal of clinical psychiatry.

A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group.

G. Tollefson, J. Potvin, J. Heiligenstein, 1995, International psychogeriatrics.

Analysis of the Hamilton Depression Rating Scale factors from a double‐blind, placebo‐controlled trial of fluoxetine in geriatric major depression

G. Tollefson, S. Holman, Gary D. Tollefson, 1993, International clinical psychopharmacology.

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized clinical trial

D. Revicki, G. Tollefson, E. Edgell, 1998, European Neuropsychopharmacology.

A comparison of human muscarinic cholinergic receptor properties subsequent to alcohol abuse and senescence.

G. Tollefson, J. Gade, 1983, Biological psychiatry.

Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.

H. Hermesh, Abraham Weizman, G. Tollefson, 2000, International clinical psychopharmacology.

Antidepressant response in chronic major depression.

G. Tollefson, M. Garvey, B. Cook, 1989, Comprehensive psychiatry.

Antidepressant treatment and side effect considerations.

G. Tollefson, 1991, The Journal of clinical psychiatry.

Olanzapine Versus Placebo in the Treatment of Acute Mania

M. Tohen, S. McElroy, G. Tollefson, 1999, American Journal of Psychiatry.

Olanzapine versus placebo in the treatment of acute mania

M. Tohen, S. McElroy, G. Tollefson, 1998, European Neuropsychopharmacology.

Olanzapine: A novel antipsychotic with a broad spectrum profile

G. Tollefson, C. Beasley, P. Tran, 1994, Biological Psychiatry.

The Neuroleptic Syndrome and Central Dopamine Metabolites

G. Tollefson, M. Garvey, 1984, Journal of clinical psychopharmacology.

Course of psychomotor agitation during pharmacotherapy of depression: Analysis from double‐blind controlled trials with fluoxetine

G. Tollefson, M. Sayler, 1996, Depression and anxiety.

Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia

D. Revicki, G. Tollefson, E. Edgell, 1999, PharmacoEconomics.

Thyroxine binding and TSH in recurrent depressive episodes.

G. Tollefson, R. Valentine, V. Tuason, 1985, The Journal of clinical psychiatry.

Time-lapse mapping of cortical changes in schizophrenia with different treatments.

Jennifer A. Geaga, J. Lieberman, G. Bartzokis, 2009, Cerebral cortex.

Ecological Studies of Antidepressant Treatment and Suicidal Risks

M. Tohen, R. Baldessarini, L. Tondo, 2007, Harvard review of psychiatry.

Time-lapse mapping of cortical changes in schizophrenia with different treatments.

Jennifer A. Geaga, J. Lieberman, G. Bartzokis, 2009, Cerebral cortex.

Health economic evaluations of antidepressants: A review

G. Tollefson, D. Buesching, T. Hylan, 1998, Depression and anxiety.

Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.

M. Tohen, S. McElroy, G. Tollefson, 1999, The American journal of psychiatry.

Olanzapine for Psychotic Conditions in the Elderly

M. Tohen, G. Tollefson, W. S. Clark, 2000 .